HIV

Latest News


Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

This discussion focuses on how to address barriers and disparities as obstacles to using PrEP, with a focus on USPSTF PrEP guidelines and ACA Part 47 for payers and providers.

Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

CME Content


The annual health information technology issue (IT) of The American Journal of Managed Care looks at the purpose for the decade-long move away from paper to technology-based infrastructure: better delivery of care to populations. As special guest editor Dr. Joshua R. Vest and other authors note, there is progress, but we’re not there yet.

Demonstrating the efficacy of antiretroviral therapies and other treatments in preventing the spread of HIV, Thomas Quinn, MD, showed that there is hope for decreasing HIV transmissions across the world. He cautioned, however, that HIV/AIDS still remains a global pandemic, and more work must be done to accelerate the rate of decrease in HIV infections.

The arrival of direct-acting antivirals to treat hepatitis C virus raised unprecedented policy questions in healthcare. This new drug class was initially met with alarm over cost and barriers to the cure, despite the potential for long-term savings, and represents one of a number of topics explored in a special issue of The American Journal of Managed Care.

CDC also published a separate study that found more people in the United States now die from hepatitis C than die from HIV or any other infectious disease. The report comes as The American Journal of Managed Care publishes a special issue on policy concerns over patient access to new therapies that cure HCV.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo